Business Context and Reporting Period
Company: Coca-Cola European Partners Plc (CCEP)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: February 14, 2021 (Filed February 16, 2021)
Context: CCEP announced a binding agreement for a revised "best and final" offer to acquire Coca-Cola Amatil Limited (CCL), a major bottler in the Asia Pacific region. This transaction aims to solidify CCEP's position as the world's largest Coca-Cola bottler by revenue.
Key Financial Metrics and Transaction Terms
- Offer Price to Independent Shareholders: A$13.50 per share in cash.
- Offer Price Increase: Represents a 5.9% increase from the prior offer of A$12.75 per share.
- Premiums: The offer represents a 36% premium to the 1-month VWAP and a 46% premium to the 3-month VWAP of CCL shares prior to the October 2020 announcement.
- Effective Price per Share: A$12.53 (incorporating the unchanged agreement with The Coca-Cola Company for its 30.8% stake). This is an increase of A$0.52 (4.3%) from the previous effective price of A$12.01.
- Target Stake: CCEP will acquire 69.2% of CCL from independent shareholders and 10.8% from The Coca-Cola Company (KO) in cash.
- Financial Position of Target: The offer revision was influenced by CCL's "improved trading and net debt position," though specific net debt figures are not provided in this filing.
Material Changes Versus Prior Period
The primary material change is the revision of the acquisition offer price. On October 26, 2020, CCEP offered A$12.75 per share. Following discussions with the CCL Board and an assessment of CCL's improved financial metrics, CCEP increased the offer to A$13.50 per share. The terms of the agreement with The Coca-Cola Company (KO) regarding its 30.8% stake remain unchanged.
Guidance, Outlook, and Risks
Management Commentary and Outlook
CEO Damian Gammell described the transaction as "strategically compelling," expected to drive sustainable growth and create shareholder value through an expanded platform and aligned partnership with KO. The transaction is not expected to significantly change the timing of the deal.
Proposed Timetable (Indicative)
- Mid-March 2021: Dispatch of Scheme booklet.
- Mid-April 2021: CCL Scheme meeting.
- Mid to Late April 2021: Effective Date.
- Late April to Early May 2021: Implementation Date.
Risks and Contingencies
- Regulatory Approvals: The scheme is subject to CCL Independent Shareholder approval, court approval, and New Zealand foreign investment regulatory approval. Australian Foreign Investment Review Board approval was received on January 29, 2021.
- Financing and Ratings: CCEP prefers to pay cash for all of KO's shareholding, subject to maintaining a solid investment-grade rating.
- Integration Risks: Risks include unsuccessful integration, higher-than-expected costs, disruption to ongoing business, and failure to retain key employees.
- General Risks: Includes impacts from the COVID-19 pandemic, regulatory changes (packaging, taxes), climate change, and economic conditions (including UK-EU relations).
Important Facts for Investor Verification
- Verify the final approval status of the New Zealand foreign investment regulatory approval and the outcome of the CCL shareholder vote scheduled for mid-April 2021.
- Confirm CCEP's credit rating status to ensure the ability to fund the cash portion of the KO stake acquisition.
- Monitor the Independent Expert's Report to ensure the scheme is deemed "fair and reasonable" for CCL independent shareholders.
- Review the specific details of CCL's "improved net debt position" in subsequent filings to understand the valuation rationale.
- Track the election date (14 days before the CCL shareholder meeting) regarding whether CCEP will acquire KO's remaining 20% interest in cash or via shares.